X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB CIPLA UNICHEM LAB/
CIPLA
 
P/E (TTM) x -62.7 39.7 - View Chart
P/BV x 0.7 3.7 19.2% View Chart
Dividend Yield % 2.4 0.5 519.6%  

Financials

 UNICHEM LAB   CIPLA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
CIPLA
Mar-18
UNICHEM LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs382663 57.6%   
Low Rs234479 48.9%   
Sales per share (Unadj.) Rs116.3189.0 61.5%  
Earnings per share (Unadj.) Rs-18.917.6 -107.5%  
Cash flow per share (Unadj.) Rs-11.734.0 -34.5%  
Dividends per share (Unadj.) Rs5.003.00 166.7%  
Dividend yield (eoy) %1.60.5 308.9%  
Book value per share (Unadj.) Rs381.0176.7 215.6%  
Shares outstanding (eoy) m70.34805.12 8.7%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x2.63.0 87.7%   
Avg P/E ratio x-16.332.5 -50.2%  
P/CF ratio (eoy) x-26.216.8 -156.3%  
Price / Book Value ratio x0.83.2 25.0%  
Dividend payout %-26.417.1 -155.0%   
Avg Mkt Cap Rs m21,668459,724 4.7%   
No. of employees `0002.323.6 9.7%   
Total wages/salary Rs m2,00626,901 7.5%   
Avg. sales/employee Rs Th3,587.86,446.1 55.7%   
Avg. wages/employee Rs Th880.01,139.4 77.2%   
Avg. net profit/employee Rs Th-583.7600.0 -97.3%   
INCOME DATA
Net Sales Rs m8,180152,193 5.4%  
Other income Rs m6103,577 17.1%   
Total revenues Rs m8,790155,769 5.6%   
Gross profit Rs m-1,32028,264 -4.7%  
Depreciation Rs m50513,228 3.8%   
Interest Rs m801,142 7.0%   
Profit before tax Rs m-1,29517,470 -7.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-28 7.9%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m332,501 1.3%   
Profit after tax Rs m-1,33114,166 -9.4%  
Gross profit margin %-16.118.6 -86.9%  
Effective tax rate %-2.614.3 -18.0%   
Net profit margin %-16.39.3 -174.8%  
BALANCE SHEET DATA
Current assets Rs m23,318108,141 21.6%   
Current liabilities Rs m4,63538,322 12.1%   
Net working cap to sales %228.445.9 497.9%  
Current ratio x5.02.8 178.3%  
Inventory Days Days12297 125.5%  
Debtors Days Days12174 163.2%  
Net fixed assets Rs m8,163109,411 7.5%   
Share capital Rs m1411,610 8.7%   
"Free" reserves Rs m26,660140,682 19.0%   
Net worth Rs m26,801142,292 18.8%   
Long term debt Rs m336,621 0.0%   
Total assets Rs m31,890228,606 13.9%  
Interest coverage x-15.216.3 -93.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.30.7 38.5%   
Return on assets %-3.96.7 -58.6%  
Return on equity %-5.010.0 -49.9%  
Return on capital %-4.510.0 -45.6%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,35651,691 8.4%   
Fx outflow Rs m021,033 0.0%   
Net fx Rs m4,35630,658 14.2%   
CASH FLOW
From Operations Rs m-1,12314,628 -7.7%  
From Investments Rs m16,487-8,540 -193.1%  
From Financial Activity Rs m-8,811-3,855 228.6%  
Net Cashflow Rs m6,5522,431 269.5%  

Share Holding

Indian Promoters % 50.1 16.0 313.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 15.1 12.2 123.8%  
FIIs % 3.0 23.7 12.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 31.7 26.2 121.0%  
Shareholders   20,176 161,166 12.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare UNICHEM LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 24, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - FRESENIUS KABI ONCO. COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS